Intravitreal injection of antibodies targeting vascular endothelial growth factor (VEGF), such as bevacizumab or ranibizumab, has been reported to improve macular edema in patients with CRVO [1,2]. The gene discussed is VEGFA; the disease is macular retinal edema.